Pharmacology, Toxicology and Pharmaceutical Science
Acute Coronary Syndrome
73%
Acute Heart Infarction
71%
Adenosine Phosphate
17%
Alendronic Acid
15%
Anticoagulant Agent
19%
Antihypertensive Agent
17%
Antiplatelet
36%
Atrial Fibrillation
53%
Bleeding
14%
Brain Ischemia
42%
Calcitonin
11%
Cardiovascular Disease
59%
Cerebrovascular Accident
76%
Cilostazol
53%
Clopidogrel
100%
Cohort Study
20%
Congestive Heart Failure
34%
Coronary Artery Disease
22%
Diabetes Mellitus
17%
Endocrine Therapy
17%
Eosinophilic Granuloma
17%
Febuxostat
17%
Fragility Fracture
17%
Galectin 3
17%
Heart Infarction
16%
Heart Left Ventricle Failure
17%
Hemodialysis
17%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
17%
Hydroxymethylglutaryl Coenzyme A Reductase Kinase
11%
Hypertrophic Obstructive Cardiomyopathy
17%
Infection
17%
Lung Infarction
17%
Non ST Segment Elevation Myocardial Infarction
13%
Observational Study
20%
Peripheral Occlusive Artery Disease
19%
Placebo
11%
Prasugrel
53%
Proprotein Convertase 9
17%
Protein Kinase
35%
Raloxifene
17%
Restenosis
17%
ST Segment Elevation Myocardial Infarction
35%
Statin (Protein)
20%
Tacrolimus
17%
Terminal Disease
17%
Ticagrelor
37%
Uric Acid
17%
Venous Thromboembolism
53%
Wegener Granulomatosis
17%
Wet Macular Degeneration
17%
Medicine and Dentistry
Acute Coronary Syndrome
20%
Acute Heart Infarction
17%
Angioplasty
17%
Antiplatelet
34%
Antithrombotic
19%
Apoplexy
71%
Arteriosclerosis Obliterans
35%
Arteriovenous Fistula
17%
Artery Disease
17%
Atrial Fibrillation
61%
Brain Ischemia
54%
Cardiology
35%
Cardiovascular System
24%
CHA2DS2-VASc Score
17%
Clopidogrel
17%
Connective Tissue Cancer
17%
Coronary Artery
17%
Coronary Catheterization
17%
Drug-Eluting Stent
35%
Emergency Medicine
17%
Eosinophilic Granulomatosis with Polyangiitis
17%
Febuxostat
17%
Genetic Risk
35%
Geriatrics
17%
Heart Left Ventricle Failure
17%
Heart Muscle Perfusion
17%
Hospital Mortality
20%
Hypertrophic Obstructive Cardiomyopathy
17%
In-Stent Restenosis
35%
Infective Endocarditis
17%
Intracoronary Drug Administration
17%
Ischemic Heart Disease
17%
Ketoconazole
17%
Kidney Denervation
17%
Lung Infarction
17%
Mean Platelet Volume
17%
Mitral Valve Stenosis
17%
Myocardial Infarction
26%
New-Onset Atrial Fibrillation
17%
Paroxysmal Atrial Fibrillation
18%
Patient Referral
23%
Percutaneous Coronary Intervention
31%
Premature Atrial Contraction
17%
Prognostic Assessment
17%
ST Segment Elevation Myocardial Infarction
35%
Thromboprophylaxis
17%
Vascular Cell Adhesion Molecule 1
17%
Vein Occlusion
17%
Venous Thromboembolism
35%
Wet Macular Degeneration
17%
Keyphrases
Acute Coronary Syndrome
20%
Adenosine Monophosphate-activated Protein Kinase Pathway
17%
Aortic Valve Rupture
17%
Atrial Fibrillation
17%
Cardiovascular Intervention
35%
Cardiovascular Therapy
17%
Clopidogrel
40%
Complex Coronary Intervention
17%
Coronary Artery Disease
19%
Coronary Artery Disease Severity
17%
Cumulative Recurrence Rate
17%
Death Records
17%
Epidemiological Characteristics
17%
Extension Catheter
17%
Febuxostat
17%
Fracture Population
17%
Genetic Risk Score
17%
Geriatric Patients
17%
Get With The Guidelines
17%
HATCH Score
17%
Infection-related
17%
Intracoronary Administration
17%
Intrathoracic Kidney
17%
Intrathoracic Liver
17%
Ischemic Stroke
22%
Major Adverse Cardiovascular Events
29%
Manual Compression
17%
Meta-analysis
17%
Metabolizer
17%
Mitral Valve Aneurysm
17%
National Cohort Study
35%
Native Valve
17%
Non-acute
17%
Non-ST-segment Elevation Acute Coronary Syndrome (NSTE-ACS)
17%
Non-surgical Management
17%
Nondiagnostic Results
17%
Paroxysmal Atrial Fibrillation
17%
Patients with Heart Failure
17%
Percutaneous Coronary Intervention
35%
Pharmacological Thromboprophylaxis
17%
PLA2G7
17%
Platelet Volume
17%
Prasugrel
35%
Pulmonary Infarction
17%
Recurrent Venous Thromboembolism
17%
Reduced Dose
17%
Right Ventricular Strain
17%
Short-term Mortality
17%
Shunt Dysfunction
17%
Taiwanese Adults
17%
